(1) Cover items | JPMA Guide Commentary | Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence

The comprehensive product information summary arranges sixteen items in a fixed, ordered format. At the very front—item ①—sits "Items to appear on the cover." Why the cover? Because it is the first page a healthcare professional looks at, the single sheet where the information that keeps a drug from being mixed up or misused must be confirmed at a glance. The Creation Guide constrains not only what goes here but how it must look. That level of detail may seem excessive, yet it is the physical implementation of the foreword's principle: convey accurately, without inviting misunderstanding.

The cover is the "face" of the material. Treat it not as a place for decoration but as a functional surface that fixes identification and the most critical safety information in the reader's first field of view.

01Why "fixed items" belong on the cover

Recall the spirit of the foreword. A Product Information Summary "complements" the (electronic) package insert and may not exceed the approved content by a single word. The cover carries the part of that approved content that identifies the drug, states its regulatory handling, and announces the dangers that must be told first. It is not a panel where the author picks what to show; it is where the reader receives, without omission, what must be checked. That is precisely why selection is not permitted and the items are fixed.

This idea runs continuous with the design philosophy of the whole Creation Guide. Even true statements can violate the rules if arrangement or omission produces a false impression. If an item is missing from the cover, the reader cannot tell whether it is "absent" or "forgotten"—and that ambiguity itself breeds misunderstanding. Fixing the items is the simplest way to prevent it.

02The basic elements on the cover

The basic elements placed on the cover can be organized into these five. Each serves to "uniquely identify the drug," "state its regulatory handling," or "state its status under health insurance."

Japan Standard Commodity Classification number — given down to the detailed classification below the middle category, descending past broad strokes to the fine division the product belongs to.
Therapeutic classification name — displayed as the product title; it must not diverge from the (electronic) package insert.
Regulatory category — the applicable category (discussed below) is written alongside the name.
Name — for products not listed in the Pharmacopoeia, the approved brand name with the generic name appended; for Pharmacopoeia products, the Pharmacopoeia name.
Whether listed in the NHI drug price list — stated as listed or not.

How the name is written splits on "Pharmacopoeia or not"

Name notation is not uniform. The basis differs between products listed in the Japanese Pharmacopoeia and those that are not. The contrast below captures the difference in handling.

Category	How the name is written
Non-Pharmacopoeia drug	Approved brand name with the generic name appended
Pharmacopoeia drug	The Pharmacopoeia name as prescribed in the Japanese Pharmacopoeia

Even within the same "name" item, what counts as authoritative differs—whether you transcribe the fact of approval or follow the name in the official compendium. This gap shows that correctness of notation is always tied to a higher norm.

03The regulatory category is written in full alongside the name

The regulatory category tells how the drug is treated under law. Where applicable, the full text of that category is written together with the name. The categories concerned include the following.

Specified biological product / Biological product
Poisonous drug / Powerful drug
Narcotic / Psychotropic / Stimulant / Stimulant raw material / Habit-forming drug
Prescription drug
Emergency approval / Special approval / Conditional approval

Why the full text rather than an abbreviation? These categories impose legal duties on the handler—restrictions on storage, recordkeeping, and dispensing. Abbreviations or omissions invite misreading and lead straight to overlooked obligations. Writing them in full on the cover is the safeguard that delivers the danger or restriction reliably "at first glance."

04Why the look of warnings and contraindications is constrained by numbers

The cover carries the full text of the (electronic) package insert's warnings and contraindications, divided into sections, placed in a conspicuous spot on the cover. And the way it must look is specified concretely.

Warnings and contraindications must be set clearly in Gothic typeface, 10 points or larger, with attention to framing, background color, and text color. A size and form that cannot be skimmed past is secured by rule, not by the author's discretion.

The Creation Guide's character shows plainly here. It specifies not only content (carry the full text) but the "look"—font, point size, frame. A fact may sit on the page, yet if it is small and unobtrusive it does not reach the reader. The visibility specification is the mechanism that secures the foreword's "accurate, without misunderstanding" at the visual level.

When there are too many contraindications to make them stand out

Sometimes the contraindications are so numerous that conspicuous presentation is physically difficult. In that case the contraindications themselves are still carried, but the reason for setting each one may be omitted. This is strictly an omission of the reasoning, not a deletion of the contraindication facts. The core that bears on safety stays; the explanatory part yields space. The priority is visible right here.

05The post-marketing surveillance mark and the RMP notice

Another role the cover carries is to announce the product's current "surveillance status."

A new drug subject to early post-marketing phase vigilance displays the unified mark on the cover for six months from launch. Right after launch, real-world data is still scarce and adverse-event information is being gathered intensively—the mark tells the reader so.
A product with a Risk Management Plan (RMP) in place states "Risk Management Plan target product" on the cover.

As the foreword indicates, a material is a "tool for safe use" before it is a "tool for selling." Both the post-marketing surveillance mark and the RMP notice distill that philosophy into a single line on the cover.

06What it means to "decide even the look"

Across the cover's rules, one thing comes into view: the Creation Guide treats "how it looks" with the same weight as "what is written." The same fact lands differently depending on placement, size, and color. Efficacy large and prominent, safety small and faint beside it—this is not a lie, but it gives a false impression. The cover's numerical specifications (10 points or larger, Gothic, framed) exist to structurally block that kind of "true but misleading" presentation.

It connects to the discipline of science. Evidence can be made to look more or less than it is by how it is emphasized. The Creation Guide constrains appearance to keep the reader able to weight information correctly—held in place by mechanism, not left to the author's goodwill. The cover is that idea in miniature.

In closing

Item ① "Items to appear on the cover" looks like a modest matter of "the first sheet," yet it is where the Creation Guide's spirit shows most densely. It fixes what is carried, requires the regulatory category in full, and decides even the size and form of warnings and contraindications. All of it serves to keep the drug from being confused and to deliver the dangers that must be told first, reliably.

Not choosing what you want to show, but never dropping what must be checked. The cover is the starting point of that discipline—and the foundation on which all fifteen remaining items stand.

Case studies — the "it isn't written, so…" mindset, and how each lands

The cover page is the first thing a reader sees, and any flaw there attaches a false premise to every page that follows. Items are fixed not to remove creative freedom but to prevent omission from becoming misinformation. Below are typical attempts to exploit the gaps in that fixed structure.

GRAY 1 — Straying from the spirit (untouched by the wording, but against the foreword's spirit)

The scheme: "The guidelines say the full regulatory-status text must appear beside the product name, but they say nothing about font size. Setting it to 9pt satisfies the rule. Oversized regulatory labels break the visual flow."

Verdict: GRAY 1. Shrinking text to near-illegibility technically "includes" the item while functionally hiding it. The cover page exists as a functional space for identification and safety confirmation — the foreword's core spirit. The correct approach is to display all required items at a size that is visually balanced and readable alongside the other mandatory elements.

GRAY 2 — Exploiting the gap (deliberately working a loophole to invite misreading)

The scheme: "Warnings and contraindications are not listed among the five required cover-page items — only classification number, pharmacological category, regulatory status, name, and NHI pricing. Putting warnings only in the DI section later doesn't violate the cover-page rules."

Verdict: GRAY 2. The five mandatory cover items are a floor, not a ceiling. A cover with no pointer to warnings creates a structural blind spot for the most critical safety information. The same logic that requires regulatory status to appear first — "convey the most essential safety signals at first glance" — requires that drugs carrying warnings direct the reader to them at the outset. The correct approach is to include a visible pointer to the warning section on or immediately after the cover page.

GRAY 3 — Violating higher norms (arguably "not in the text," yet almost certainly out under the PMD Act, Fair Advertising Standards, and the JPMA Code)

The scheme: "The guidelines say the pharmacological category name must match the package insert, but adding a single upbeat tagline below it is just a design element — not a 'required cover item' and not a 'promotional claim.'"

Verdict: GRAY 3. Any wording on the cover that creates an impression beyond the approved labeling falls under the PMD Act Article 66 (false or exaggerated advertising) and the JPMA Promotion Code's prohibition on off-label information. The category "design element" has no legal standing; regulators assess the overall impression the reader receives. The correct approach is to confine every word on the cover to the exact terms used in the approved package insert.

BLACK — Breaching the explicit text (a plain violation of the provision itself)

The scheme: "The rule says to add the non-proprietary name next to the approved trade name, but a branded abbreviation that resonates better with prescribers accomplishes the same purpose — the name is still there."

Verdict: BLACK. The guidelines explicitly state: for non-pharmacopoeia products, add the non-proprietary (INN-based) name to the approved trade name; for pharmacopoeia products, use the pharmacopoeia name. A proprietary abbreviation is none of these, and directly contravenes the provision. It also risks drug-identification errors in clinical practice.

Improper intent by implication — three scopes of "insinuating" without stating it

The cover is the first page a healthcare professional sees. Because the guidelines regulate not only what to write but how it must appear, their purpose can be subverted through visual design: safety information is technically present but practically invisible. The three examples below achieve improper guidance without violating any explicit prohibition.

Implication 1 — Local: carried in a single word or sentence

How it is built: "Warnings and contraindications are set in 8-point type while the product name and indication appear in 16-point bold, both on the same page."

Intent that can be read: Safety information "exists" but need not be read. The contrast in type size alone manipulates where the eye goes, reducing the warning to a formal checkbox.

Verdict: The guidelines require warnings and contraindications to be "clearly shown in a red box, bold type, etc." Reducing legibility through small type violates that purpose. Safety information must be set in a size that does not impair readability.

Implication 2 — Adjacent: read across neighboring clauses

How it is built: "Product photo (large) → approved indication (one line) → strength/dosage form → warnings and contraindications (same size, same color) displayed in a horizontal sequence that fixes reading order through layout."

Intent that can be read: Attention-grabbing visuals and the indication are placed first; safety information appears after the reader's eye has already moved on. Even identical type sizes yield very different read-through rates depending on position.

Verdict: The guidelines' purpose is to make safety information confirmable "at a glance, without confusion." Warnings and contraindications must be positioned at least as prominently as product-identification elements, not after them.

Implication 3 — Whole-context: arising from the document as a whole

How it is built: "The entire cover is designed with a high-resolution product visual and brand colors; warnings and contraindications are placed in a box tinted close to the background, blending into the overall visual theme."

Intent that can be read: By framing the cover as a brand experience, the safety box becomes just another design element. No individual text violates a rule, but the overall visual tone deliberately minimizes the presence of safety information.

Verdict: The guidelines specify red boxes and bold type to ensure the warning stands out independently of the surrounding design. A color scheme or box style that blends into the background does not constitute "clear display." Safety information must contrast visibly against whatever design surrounds it.